Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Diffuse Cutaneous Systemic Sclerosis (BRAVOS)
NCT03222492Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2017
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2017; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT03222492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222492.